Dow, S&P 500, Nasdaq futures fall ahead of shortened week with AI disruption fears in focus

🧬 FDA delays Disc Medicine’s rare disease drug

Disc Medicine Inc. shares closed around 22% lower on Friday as the company navigates a regulatory hiccup with a Complete Response Letter from the US Food and Drug Administration regarding its drug bitopertin.

On Tuesday, the stock is trading higher.

Bitopertin has been under review for accelerated approval and as part of the Commissioner’s National Priority Voucher pilot program.

In January, FDA reviewers postponed their decision on bitopertin by about two weeks to February 10.

Regulators questioned whether “pain-free time in the sun,” a secondary endpoint in trials, was a statistically reliable measure of effectiveness or whether biomarker data could instead support approval. Benzinga reports.


🩺 Masimo stock soars as Danaher closes in on blockbuster deal

Danaher Corp. is reportedly nearing a roughly $9.9 billion acquisition of Masimo Corp., a move that follows significant governance changes at the medical device maker driven by activist investors.

A transaction for the California-based Masimo could be announced as early as Tuesday, the Financial Times reported, provided there are no last-minute complications, according to people familiar with the matter.

The deal represents a notable premium to Masimo’s nearly $7 billion market capitalization as of Friday’s close.

The potential deal comes two years after activist hedge fund Politan Capital Management led a proxy contest that resulted in the removal of founder Joe Kiani as board chair. Finviz reports.


🚢 ZIM stock soars 34% after Hapag-Lloyd agrees takeover. Why the market loves it

ZIM Integrated Shipping Services stock surged on Tuesday after German shipping giant Hapag-Lloyd said it had agreed to buy its U.S.-listed Israeli rival for $4.2 billion.

The deal sparked strong investor enthusiasm, driving sharp gains in ZIM shares as markets welcomed the takeover premium and the strategic consolidation in global container shipping. Barron’s reports.


👁️ OCUL stock surges overnight ahead of crucial wet AMD data readout as Sanofi takeover buzz builds

Shares of Ocular Therapeutix surged nearly 40% in overnight trading on Monday ahead of the company’s release of late-stage clinical data in wet age-related macular degeneration, a catalyst that analysts and investors have been closely tracking for months.

The results come at a time when Ocular Therapeutix has also been in focus following reports that Sanofi is revisiting a potential acquisition of the eye drug developer, after an earlier approach at $16 per share was declined when the stock was trading near $10.5, implying a valuation of about $2.2 billion. StockTwits reports.


🧠 CMPS stock jumps 22% premarket as Compass sets timeline for new phase 3 depression trial results

Compass Pathways shares were up nearly 22% in Tuesday’s premarket trade ahead of the company’s announcement of new clinical data from two of its ongoing phase 3 trials.

Compass announced on Monday that it will report new clinical data from two ongoing phase 3 trials evaluating COMP360 for treatment-resistant depression.

The company will release the data at 6:30 a.m. ET, before the regular trading session begins. StockTwits reports.


🚚 Algorhythm Holdings’ stock triples on AI freight tool rollout: three things retail investors are watching

Algorhythm Holdings, once an in-car karaoke supplier that last year pivoted the business to a freight management tech platform, stunned the market with a 222% rally on Friday.

Now, investors are asking whether there’s any more juice left and what the path forward is for the stock.

Here are the top focus points with retail traders, according to chatter on Stocktwits. StockTwits reports.

*Estimate and Actual numbers represent Earnings Per Share in US Dollars


NEO: NeoGenomics
Q4 2025
Before Market Open
Estimate: 0.010
Actual: N/A

MDT: Medtronic
Q3 2026
Before Market Open
Estimate: 1.330
Actual: N/A

SUN: Sunoco
Q4 2025
Before Market Open
Estimate: 1.560
Actual: N/A

Time (ET) / Report / Period

8:30 AM - Empire State manufacturing survey - Feb.
10:00 AM - Home builder confidence index - Feb.

“The cost of being early is often the same as being wrong.”

– Vijay Kedia

Sourced in: Vijay Kedia interview – CNBC TV18.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.